Not yet recruiting
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
NCT07738887· Phase 2· The Lymphoma Academic Research Organisation· Source
Not yet recruiting
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer
NCT07759492· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Not yet recruiting
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00· Phase 3· Fondation A De Rothschild· Source
Not yet recruiting
Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2
2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source
Not yet recruiting
Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).
NCT07624799· Phase 2· French Innovative Leukemia Organisation· Source
Recruiting
Evaluation of Depression Screening Methods Administered by Registered Nurses in Chronic Hemodialysis Patients
NCT07651436· Centre Hospitalier Annecy Genevois· Source
Contact: Marie-Christine CARRET
Recruiting
Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO Project
NCT07418827· Assistance Publique Hopitaux De Marseille· Source
Contact: Romain JAILLER
Recruiting
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
NCT06656598· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Recruiting
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
NCT06918002· Phase 3· Intergroupe Francophone du Myelome· Source
Recruiting
Identification of Pre-surgical Phenotypic Indicators Predictive of Quality of Life Trajectories in Obese Patients Following Bariatric Surgery
NCT06951893· Centre Hospitalier Metropole Savoie· Source
Contact: Fabienne PRIEUR
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277· Phase 3· AstraZeneca· Source
Recruiting
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
NCT06561854· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
NCT06552234· Phase 2· Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer· Source
Recruiting
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT06428019· Phase 3· AbbVie· Source
Recruiting
Colchicine Versus Placebo in Acute Myocarditis Patients
NCT05855746· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
2023-505436-35-00· Phase 3· Lysarc· Source
Recruiting
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00· Phase 3· Institut Gustave Roussy· Source
Active, not recruiting
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Recruiting
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
NCT05753384· Phase 3· Poitiers University Hospital· Source
Active, not recruiting
Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
NCT05856695· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Active, not recruiting
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
NCT05199051· Phase 2· Centre Antoine Lacassagne· Source
Active, not recruiting
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
NCT04790253· European Organisation for Research and Treatment of Cancer - EORTC· Source
Contact: EORTC Reception
Active, not recruiting
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence
NCT05297617· Phase 2· Unicancer· Source
Recruiting
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
NCT04916613· Phase 3· UNICANCER· Source
Active, not recruiting
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
NCT05135559· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
MInimal Residual Disease Adapted Strategy
NCT04934475· Phase 3· Intergroupe Francophone du Myelome· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
NCT04712097· Phase 3· Hoffmann-La Roche· Source
Recruiting
Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
NCT04954820· Phase 2· Institut du Cancer de Montpellier - Val d'Aurelle· Source
Recruiting
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
NCT04325425· Phase 2· Centre Hospitalier Universitaire Dijon· Source
Active, not recruiting
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, high burden disease: chemotherapy and combination of hormonotherapy with abemaciclib.
NCT04158362· Phase 3· Unicancer· Source
Recruiting
Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up
NCT04290663· Phase 3· Centre Francois Baclesse· Source
Active, not recruiting
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy
NCT04181203· Phase 3· UNICANCER· Source
Recruiting
French Registry for Monitoring Pregnancies for Multiple Sclerosis
NCT03900221· Hospices Civils de Lyon· Source
Contact: Clara GROSSET-JANIN
Active, not recruiting
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
NCT03977194· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source
Completed
PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS
NCT03895671· Phase 2· Versailles Hospital· Source
Active, not recruiting
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck
2024-513206-65-00· Phase 3· Groupe Oncologie Radiotherapie Tete Cou· Source
Completed
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT03079011· Phase 3· UNICANCER· Source
Active, not recruiting
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy
NCT02889523· Phase 1/2· The Lymphoma Academic Research Organisation· Source
Active, not recruiting
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 and older
NCT02355379· Phase 2· Fondation Franc.Cancerologie Digestive· Source
Active, not recruiting
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
NCT01952223· Phase 3· UNICANCER· Source
Active, not recruiting
Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18)
NCT00967863· UNICANCER· Source